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Primary systemic therapy for operable breast cancer -
1 Oyear survival data after chemotherapy and hormone
therapy
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Summary Between 1984 and 1990, 94 women presenting to the Edinburgh Breast Unit with operable breast cancer of 4 cm or greater in
diameter (T2, T3, NO, Ni, MO) were given preoperative systemic therapy. Initially, all women received hormone therapy, with CHOP
(cyclophosphamide 1 g m-2, doxorubicin 50 mg m-2, vincristine 1.4 mg m-2 to a maximum of 2 mg and prednisolone 40 mg per day orally for 5
days) chemotherapy being administered to those who failed to respond by 3 months. After April 1987, first-line hormone therapy was only
offered to women with oestrogen receptor (ER)-moderate/-rich (> 20 fmol mg-1 protein) tumours, and CHOP was reserved for those women
whose tumours failed to respond to hormone therapy and for those with ER-negative/-poor tumours. Response data have been published
previously (Anderson et al, 1991). After a median follow-up of 7.5 years, there is no difference in survival between those women given initial
hormone therapy and those given chemotherapy, with neither group having yet reached its median survival. The two key factors that predicted
for a poor survival were the number of involved axillary nodes after preoperative systemic therapy (P < 0.00001) and a lack of response to
preoperative therapy (P < 0.05). These data suggest that many women with ER-moderate/-rich tumours will have a good prognosis after
preoperative hormone therapy alone. However, it is possible to identify, by their post-systemic therapy axillary node status, a group of women
who still have an appalling prognosis after preoperative chemotherapy or hormone therapy.
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The role of adjuvant therapy in operable breast cancer has been
firmly established over the past few years, in no small part because
of the meta-analyses published by the Early Breast Cancer
Trialists' Collaborative Group (Early Breast Cancer Trialists
Collaborative Group, 1992). However, the combination of
hormone and chemotherapy that is optimal for an individual
patient cannot be identified from such overviews. Conventionally,
such adjuvant therapy is offered after definitive surgery, but many
groups would now accept that preoperative systemic therapy is not
detrimental to survival, and some reports suggest a possible
survival advantage (Mauriac et al, 1991; Scholl et al, 1994). There
is also the potential advantage that a response in the primary
tumour may reflect drug-sensitive disease and hence a survival
benefit for the patient. Therefore, in 1984, the Edinburgh Breast
Group commenced a phase II study of preoperative therapy that
was to be hormone based whenever possible (Forrest et al, 1986;
Anderson et al, 1991), with the intention of identifying, by the
primary tumour response, women with hormone-sensitive disease
for whom adjuvant hormone therapy alone might be adequate. If
the primary tumour did not respond, treatment was changed to
chemotherapy. Reports of this study, which led to the initiation
of the current randomized trial comparing this approach with
conventional post-operative adjuvant therapy (Forouhi et al,
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1995), appeared in 1986 (Forrest et al, 1986) and 1991 (Anderson
et al, 1991). This paper reports the long-term follow-up of the
original study and determines the facets of tumour response that
best predict for long-term survival.
PATIENTS AND METHODS
The patients and methods used have been described in detail previ-
ously but will be briefly summarized. Ninety-four women with
operable breast cancer (T2, T3, NO, NI, MO) with a minimum
tumour diameter of 4 cm were treated on the same protocol. Fifty-
four (53%) were clinically T2 and the remainder T3. All patients
were of ECOG performance status 0, and their tumours had
no evidence of fixation to skin or pectoral muscle, of skin
lymphoedema or of metastases on routine staging (including bone
scan). The median age was 53 years (range 33-72 years), and all
patients gave verbal informed consent to enter the study.
Clinical assessment of tumour size was based on the tumour
volume, as defined by a sphere whose diameter was the mean of
eight calliper measurements at 22.50 axes. The initial measurements
were taken before diagnostic fine-needle aspiration. After routine
staging tests, a clinically malignant ipsilateral axillary node was
excised (16 patients) or a pretreatment wedge biopsy was performed
(78 patients); in 28 out of 78 patients, a lower axillary node sample
was also performed. The oestrogen receptor (ER) concentration was
estimated on the excised tumour tissue by the dextran coated
charcoal (DCC) adsorption method (Hawkins et al, 1990).
The first 40 patients all received initial hormone therapy (12
had tamoxifen 20 mg daily, 12 had goserelin 3.6 mg every
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Table 1 Preoperative treatments (numbers of patients)
ER negative poor (< 20 fmol mg-') ER positive rich (> 20 fmol mg-') Total
Primary chemotherapy 28 0 28
Primary hormone therapy 18 48 66
Aminoglutethimide 5 7 12
Tamoxifen 4 8 12
Medical/surgical oophorectomy 9 17 26
4-Hydroxy-androstenedione 0 16 16
Secondary chemotherapy 12 10 22
4 weeks, 12 had aminoglutethimide (AMG) 1 g with hydrocorti-
sone 30 mg daily and four had a surgical bilateral oophorec-
tomy); but, after April 1987 [when it was appreciated that
there were no significant responses to hormone therapy in
ER-negative/-poor tumours (Anderson et al, 1989)], this was
reserved for patients whose tumour had an ER concentration
of > 20 fmol mg-' cytosolic protein, whereas those with ER-
negative/-poor tumours received four courses of 3-weekly CHOP
chemotherapy (cyclophosphamide 1 g m-2, doxorubicin 50 mg m-2,
vincristine 1.4 mg m-2 to a maximum of 2 mg and prednisolone
40 mg per day orally for 5 days). This was continued for
12 weeks (see Table 1).
Response assessment
Regression line of tumour volumes
After starting preoperative systemic therapy, patients were seen
weekly and tumour measurements were made with callipers.
Fifteen patients had evidence of progressive disease while
receiving hormone therapy, which was therefore stopped, and
in 13 patients treatment was immediately changed to
chemotherapy; two patients proceeded, at their own request,
directly to mastectomy. In the remaining patients, tumour
response was assessed at 12 weeks by regression analysis of the
tumour volumes from weeks 4 to 12. Using 95% confidence
intervals, those tumours that had a regression line with a signifi-
cantly negative gradient were classified as responding, whereas
those that had a significantly positive gradient were classified as
progressing (Anderson et al, 1991; Cheung and Johnson, 1991).
Any tumour whose regression line was not significantly deviant
from the horizontal was classified as static. Patients with
tumours that were static or progressing on hormone therapy
proceeded to 12 weeks' chemotherapy with CHOP before
locoregional surgery. Definitive locoregional treatment was to
have comprised modified radical mastectomy in all cases, but in
six patients with a complete clinical response a wide local exci-
sion of the primary tumour site was performed. Post-operative
radiotherapy was given to five out of six patients having breast-
conserving surgery and 10 out of 88 of those having mastectomy.
After surgery, those patients whose tumours had responded
to hormone therapy were continued on hormone therapy, with
premenopausal women undergoing a surgical oophorectomy and
post-menopausal women being given tamoxifen 20 mg daily
until first recurrence. No further chemotherapy was given to
those who had received CHOP preoperatively.
Time to halve tumour volume
The above method of assessing response takes no account of the
rate at which a tumour regresses. Therefore, we have retrospec-
tively considered a second measure of response, the time taken on
therapy for the volume of the primary tumour to fall (and remain)
below half the initial volume. For hormone-treated tumours, it is
easy to determine this time but, for those tumours treated with
chemotherapy, response can be rapid and obscured during the first
4 weeks by bruising after wedge biopsy. Therefore, the clinically
useful time of 42 days (i.e. after two cycles of treatment) was used
as an assessment point, whereas hormone-treated tumours were
categorized by whether or not they had halved their volume during
the 3-month duration of the treatment.
Patients were followed up by the Edinburgh Breast Unit and
data were available for 90 patients on or after 31 December 1995,
with four patients being lost to follow-up during 1992 and 1993.
The median follow-up of all patients is 7.5 years. The cause of
death was recorded as breast cancer in all patients with known
metastatic disease.
Statistical methods
All survival analyses have been performed using the
Kaplan-Meier method and statistical comparisons using the
log-rank test; this was done using the 'Sureal' programme
(W Gregory, personal communication) running under MS-DOS
6.2 (Microsoft). The Cox multivariate analysis was performed
using a programme written by W Gregory (personal communica-
tion), with variables treated both as continuous and discrete with
break-points as indicated in Table 3. Comparison of the number of
involved nodes after surgery by type of treatment was performed
using the Mann-Whitney test in Minitab version 5.1.1 (Minitab,
State College, PA, USA) running on the same computer.
RESULTS
Overall survival is seen in Figure 1; the actuarial 10-year survival
is 55%, and the median survival has not yet been reached. Disease-
free survival is also shown in Figure 1. The median disease-free
survival is 9 years 4 months. At the end of 1995, a total of 41
patients had relapsed. This included 15 patients with locoregional
relapses, of whom 13 had also developed systemic disease.
Twenty-six patients have developed only distant disease. Of the 39
patients who have developed overt metastatic disease, only four
are still alive. There is no difference in survival for patients by
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Figure 1 Overall and disease-free survival for all 94 patients
initial tumour size or T stage (X2 = 0.86, P > 0.1), ER status (%2 =
0.01, P > 0.1) nor initial preoperative treatment (chemotherapy or
any mode of hormone therapy; X2 = 0.98, P > 0.1), irrespective of
the age of the patients.
Axillary node involvement
Forty-two women had had at least one axillary node removed
before treatment, and there was a trend for a worse overall survival
(x2 = 3.39, P = 0.07; data not shown) in those 31 (74%) women
with histologically confirmed nodal metastases before treatment.
There was no difference in the pretreatment axillary nodal status
for the women receiving different initial systemic therapies, nor
for women with tumours of different ER values. Table 2 summa-
rizes the data for these women. Of the 11 women without initial
evidence of axillary metastases, two were later found to have
positive nodes (and two more had no further axillary surgery). In
contrast, 18 out of 31 (58%) of the women with initial evidence of
axillary nodal metastases had evidence of persisting involvement
at the time of their definitive surgical treatment. However, conver-
sion of women who were initially node positive to being node-
negative occurred significantly more often after chemotherapy,
with none of the 13 such women having only received hormone
therapy (P < 0.01, Fisher's exact test) (see Table 2), although four
had had both endocrine and chemotherapy.
Survival by post-treatment axillary node status is shown in
Figure 2. There are no long-term survivors with ten or more
Figure 2 Overall survival of all 94 patients grouped by the number of
involved axillary nodes after preoperative systemic therapy. X2 = 40.01,
P < 0.00001
involved axillary nodes, whereas the 10-year survival for those
patients with one to three and four to nine involved nodes are 52%
and 18% respectively. In a Cox multivariate analysis, the number
of involved axillary nodes after treatment is the only significant
variable included at the 5% level (see Table 3). Furthermore, the
median number of involved nodes in the axillary clearances of
those women receiving chemotherapy was zero, which was
significantly less than those who only received hormone therapy
(median number of involved nodes, one) (W = 565, P < 0.025) or
those receiving both modalities (median number of involved
nodes, two) (W= 1664, P < 0.05).
Response to primary chemotherapy
For those tumours treated by chemotherapy, the overall response
rate was 70% (sgee Table 4). The response rate to chemotherapy is
lower at 50% after a failure of hormone therapy. Pathological
complete responses (pCR) were seen in 7 out of 28 (25%) patients
treated with primary chemotherapy and a further one (5%) patient
who had chemotherapy after hormone therapy, giving an overall
pCR rate of 16% for chemotherapy. Of these patients, seven
remain disease free and one has died of malignant leptomeningeal
disease, pathologically distinct from her primary breast cancer. In
contrast, no patient achieved pCR on hormone therapy alone.
Response to chemotherapy, as assessed by regression analysis,
Table 2 Pre- and post-treatment node status
Post-operative node status
Hormone therapy only Chemotherapy
Negative Positive ND Negative Positive ND Total
Preoperative
Node negative 2 2 1 5 0 1 11
Node positive 0 8 0 13 10 0 31
Total 2 10 1 18 10 1 42
ND, not done.
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Table 3 Cox multivariate analysis of predictors for poor survival
X2 P-value
Post-treatment number of nodes 12.68 < 0.0005
(all other variables had P-values > 0.1, except second treatment where P = 0.09)
Variables considered with cut-offs: age, 40 years; initial tumour size; T stage; ER concentration,
20 fmol mg-'; post-treatment number of involved nodes, one, four and ten; initial treatment; initial response;
second treatment; response to secondary chemotherapy; time to halve tumour volume, 42 and 90 days for
chemotherapy and hormone therapy respectively.
Table 4 Response to preoperative treatment
Hormone therapy Chemotherapy
ER-positive/-rich tumours ER-negative/-poor tumours All hormone therapy 10 20 All
n (%) n (%) n (%) n (%) n (%) n (%)
CR 1 (2) 0 (0) 1 (2) 8 (29) 5 (23) 13 (26)
PR 24 (50) 1 (6) (ER unknown) 25 (38) 16 (57) 6 (27) 22 (44)
SD 17 (45) 5 (28) 22 (33) 4 (14) 8 (36) 12 (24)
PD 5 (10) 9 (50) 14 (21) 0 (0) 0 (0) 0 (0)
U/K 1 (2) 3 (17) 4 (6) 0 (0) 3 (14) 3 (6)
CR, complete remission; PR, partial response; SD, stable disease; PD, progressive disease; U/K, data unavailable.
does not give a statistical survival advantage (%2 = 2.27, P > 0.1)
but, if those patients with a pCR are included as a separate group
(and they cannot of course be identified on the basis of the tumour
volume regression line alone), then there are significant differ-
ences between the three groups (see Figure 3). Furthermore, a
more rapid response (as assessed by the time to halve the tumour
volume) is also seen to be associated with a better survival (see
Figure 4). That these two methods of response assessment are not
synonymous is clear from the observation that 3 out of 11 patients
with slower responding tumours had been categorized as a partial
response (PR) by regression analysis, whereas 3 out of 36 of those
with faster responding tumours were in fact non-responders, as
determined by the regression line method.
It is of interest to note that for the women given chemotherapy
who had no evidence of axillary nodal involvement after treat-
ment, there was no difference in survival between those with a
primary tumour pathological complete response and those without
(X2 = 0.002, P > 0.5); in particular, of the three women with pCR
who had had a pretreatment axillary node sample, two had had
positive nodes.
Response to primary hormone therapy
The response rate for all hormone-treated tumours was 40%,
which rose to 52% for those tumours that were ER moderate/rich
(see Table 4). The overall survival of those women who responded
to hormone therapy (and thus were not given chemotherapy)
was no different from those women who received primary
chemotherapy (see Figure 5). However, the overall response of the
primary tumour to hormone therapy does not seem to predict for
survival (%2 = 0.5 and X2 = 0.1 1, P > 0.1 for ER-moderate/-rich and
for all tumours respectively). Nevertheless, when the rate of the




















Figure 3 Survival for all patients given chemotherapy, as grouped by their
response (pCR, n= 8, CR and PR, n = 30; SD and PD, n = 9). X2 = 8.01,
P= 0.005
required to halve the tumour volume, there is seen to be a survival
advantage for those tumours that responded more rapidly (see
Figure 6). Patients who failed to respond to hormone therapy and
therefore also received chemotherapy not only had a poorer
response rate but also a worse survival compared with those only
requiring a single systemic treatment modality before surgery
(Figure 7).
A Cox multivariate analysis was performed using the variables
listed in Table 3, and this confirms that it is only the number of
involved nodes in the post-treatment axillary clearance that is a
significant predictor of outcome, irrespective of the use of discrete
or continuous variables.
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Figure 6 Survival of patients with ER-positive tumours that had halved their
volume within 90 days' treatment (n = 34) compared with those that had not
(n = 30) during primary endocrine therapy. X2 = 4.667, P < 0.05
DISCUSSION
Originally, this study was undertaken to ascertain whether the
response to preoperative hormone therapy could be used to select
long-term adjuvant therapy. However, ER-negative/-poor tumours
had a very low response rate to hormone therapy (Anderson et al,
1989), and thus women with such tumours after April 1987
received only chemotherapy. Furthermore, no altemative therapy
was offered to the 14% of patients whose tumours did not respond
to CHOP. Hence, women with hormone-sensitive tumours were
treated with only hormone therapy, whereas those with a priori
or manifest hormone resistance also received preoperative
chemotherapy. Although no firm conclusion can be drawn about
the relative efficacies of the administered treatments, observations
on the relationship of response and outcome are valid.
Preoperative administration of systemic therapy might theoreti-
cally improve survival. Since this study was commenced, three
randomized trials comparing pre- and post-operative chemotherapy
have reported survival data: one study found an initial clear
.-4
*|.1S.;-1
Figure 5 Survival of patients who responded to endocrine therapy (n= 26)
compared with those given preoperative chemotherapy (n 50). x2 0.59,
P> 0.4
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Figure 7 Survival of all patients by their preoperative treatment: single
modality (chemotherapy or endocnne) (n 72) or both modalities (n = 22).
X2 4.690,P'< 0.05
survival advantage, later lost, for preoperative systemic therapy
(Scholl et al, 1994, 1995); another study reported only a disease-
free survival advantage for the preoperatively treated group
(Semiglazov et al, 1994); and the third study did find a survival
advantage, but 23% of those in the control arn received no
systemic adjuvant therapy and these patients constituted 10% of the
relapses (Mauriac et al, 1991). Comparison of our data with histor-
ical controls of post-operative adjuvant chemotherapy is unreliable
but does not suggest that the women have fared worse than patients
treated either with (Morrison et al, 1989; Tormey et al, 1992) or
without a doxorubicin based regimen (Fisher et al, 1969).
The number of involved nodes in the ipsilateral axilla is an indi-
cator of a poor prognosis not only after adjuvant therapy but also
with preoperative chemotherapy for both locally advanced (Grdhn
et al, 1984; Gardin et al, 1995) and large operable breast cancer
(Botti et al, 1995); furthermnore, in these studies of preoperative
therapy, it was, as in this study, the prognostic factor with the
British Journal of Cancer (1997) 76(8), 1099-1105
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highest level of statistical significance. However, the only report
(although without statistical analysis) of similar 10-year survival
rates for primary doxorubicin-based chemotherapy is from the MD
Anderson Hospital, where women with stage III breast cancer had
survival rates of 65%, 44%, 32% and 9% when there were, respec-
tively, no, 1-3, 4-9 and 10 nodes still involved after chemotherapy
(Frye et al, 1995). In general, our patients were at an earlier stage,
which may explain the better survival of our patients with few
involved nodes; equally, the small number (24) of patients with
four or more involved nodes produces wide confidence intervals
and thus perhaps the apparently worse survival in our series.
This study did not permit full knowledge of the patients' preop-
erative axillary nodal status. Thus, the prognostic importance of
the number of nodes still containing tumour after preoperative
systemic therapy could simply be a reflection of the number
involved at presentation, although some nodes might have been
cleared of their metastases by the therapy - as suggested by the
finding that there were fewer involved nodes in patients in the
preoperative therapy arm of the NSABP B-18 study (Fisher et al,
1994). Consistent with this are the treatment-related differences in
the post-treatment axillary node status observed in this study, with
relatively fewer involved nodes after primary chemotherapy, and
the observation that significantly more of the women with pretreat-
ment but no post-treatment axillary involvement had been given
chemotherapy. It is not possible, however, to separately identify
those patients in whom all the histologically involved nodes had
been removed by the pretreatment sampling. Thus, the absence of
involved nodes may, at least in some cases, be a reflection of drug
sensitivity, and the Cox multivariate analysis reveals it to be a more
sensitive marker than clinical tumour response. This has potential
implications for patients with clinical CR after neoadjuvant
therapy, on which there is current debate (and a randomized trial)
assessing the need for surgery to the breast and axilla.
Figures 3 and 4 confirm that, for patients given chemotherapy,
response is associated with a survival advantage, as has been
previously noted (Jacquillat et al, 1990; Calais et al, 1993; Scholl
et al, 1996), with the best group being those with a pathological
complete remission, as suggested by the data of Bonadonna et al
(1993). For the tumours treated with hormone therapy, Figure 6
suggests that response is associated with a survival advantage, but
only when assessed by the rate of regression; this may be because
hormone therapy is in general slower to induce a response than
chemotherapy. A survival advantage for hormone sensitivity when
treating with primary tamoxifen has been previously noted in
elderly women (Horobin et al, 1991).
In the current study, 58% of the tumours failed to respond to
hormone therapy, and 22 out of 29 went on to receive CHOP, with
a reduced response, and higher persisting nodal burden rate
compared with primary chemotherapy. This apparently worse
response rate to chemotherapy after failed hormone therapy has
also been noted in metastatic disease (Swenerton et al, 1979).
Impaired response to chemotherapy in untreated ER-moderate/
-rich tumours has been previously noted (Bonadonna et al, 1990;
Mauriac et al, 1991; Belembaogo et al, 1992). However, the
known effects of hormone therapy upon breast cancer could
further prejudice the subsequent response to chemotherapy.
Tamoxifen has been reported, irrespective of the level of ER, to
cause a fall in the proliferation rate of breast cancers (Clarke et al,
1993), and the response to preoperative chemotherapy is poorer in
tumours with low rates of proliferation (Remvikos et al, 1993).
Furthermore, there is a study in elderly women that reports an
increase in P-glycoprotein after three months' tamoxifen (Keen et
al, 1994), suggesting another possible mechanism for reduced
sensitivity to chemotherapy. Hence, there are grounds for concern
that pretreatment with hormone therapy, particularly in an ER-
moderate/-rich breast cancer, might prejudice the response to any
subsequent chemotherapy.
In contrast, the patients who received only hormone therapy had
an equivalent survival to those who received only chemotherapy.
Patients were not allocated to these two treatment modalities at
random, but rather on the basis of their ER concentration; there-
fore, firm conclusions cannot be drawn, but the ER concentration
is itself not a predictor for long-term survival (Pichin et al, 1996).
Furthermore, it remains unclear whether additional chemotherapy
would have been beneficial. The dilemma is that hormone thera-
pies are in general better tolerated, but one cannot identify before
treatment those ER-moderate/-rich tumours that will not respond;
there were no differences in the ER value between the responders
and the non-responders, and there were no other useful predictors
for hormone sensitivity. Furthermore, it would appear to be the
post-treatment axillary node status that best identified patients
with a poor outcome.
This study confirms that although primary tumour response to
preoperative systemic therapy is associated with a survival advan-
tage, it is the number of involved axillary nodes after systemic
therapy that best discriminates prognostic groups, with all node-
negative patients having a similar survival irrespective of the
primary tumour pathological response. Thus, after preoperative
systemic therapy, whether it is hormone or chemotherapy based,
the persistence of involved axillary nodes confers an appalling
prognosis, and new drugs or therapeutic strategies, possibly
including high-dose chemotherapy, need to be tested in these
women in randomized studies.
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